Research Progress of Immunotherapy for Non-small Cell Lung Cancer
with Drive Gene Mutation.
10.3779/j.issn.1009-3419.2022.102.06
- Author:
Renfang DENG
1
;
Yue ZENG
1
;
Yue PAN
1
;
Chunhong HU
1
;
Fang WU
1
Author Information
1. Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
- Publication Type:Review
- Keywords:
Driver gene;
Immune therapy;
Lung neoplasms
- MeSH:
Carcinoma, Non-Small-Cell Lung/therapy*;
Humans;
Immunotherapy;
Lung Neoplasms/therapy*;
Molecular Targeted Therapy;
Mutation
- From:
Chinese Journal of Lung Cancer
2022;25(3):201-206
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most lethal malignancy around the world and non-small cell lung cancer (NSCLC) accounts for 80% of all cases. Most of the NSCLC patients has "driver gene mutations" and targeted therapy achieved a relatively good efficacy, but some patients progressed or relapsed after treatment. Previous studies demonstrated that immune checkpoint inhibitor could improve the prognosis of advanced-stage NSCLC and prolong the survival time. However, the efficacy of immune therapy varies in NSCLC patients with different immune and molecular features. The efficacy of immune therapy was controversial in NSCLC patients with driver gene mutation. The present review will summarize the immune characteristics of NSCLC patients with driver mutation and the directions of immunotherapy for patients with driver mutation.
.
